|
Bevacizumab (Bev) to reduce the negative impact of glioblastoma (GBM) tumor size on survival from first recurrence. |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Agios; Bristol-Myers Squibb; Nativis; Northwest Biotherapeutics; Omniox; Roche/Genentech; Siemens |
Research Funding - Roche/Genentech; Siemens |
Travel, Accommodations, Expenses - Nativis; Omniox; Siemens |
| |
|
Consulting or Advisory Role - Novocure |
| |
|
No Relationships to Disclose |
| |
|
|
Stock and Other Ownership Interests - Genentech |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Research Funding - Genentech/Roche; GlaxoSmithKline |
| |
Timothy Francis Cloughesy |
Stock and Other Ownership Interests - Notable Labs |
Consulting or Advisory Role - Abbvie; Agios; Alexion Pharmaceuticals; Boston Biomedical; Bristol-Myers Squibb; Celgene; Celldex; cortice; CytRx Corporation; Human Longevity, Inc; Insys Therapeutics; Merck; Nektar; NewGen Therapeutics; Notable Labs; Novartis; Novocure; Novogen; Oxigene; Pfizer; ProNAi; Roche/Genentech; Sunovion; Tocagen; Upsher-Smith; VBL Therapeutics; wellcome trust |
| |
|
Consulting or Advisory Role - Abbvie; Genentech/Roche; Novocure |
Research Funding - Genentech/Roche |